# Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

> **NCT02109445** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Cancer Pancreas

## Interventions

- **DRUG:** PF-03084014
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** PF-03084014
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02109445
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-03
- **Primary completion:** 2014-11-06
- **Final completion:** 2014-11-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No safety/efficacy concerns were behind the reason of trial termination
- **Last updated:** 2019-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109445, "Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02109445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*